Last reviewed · How we verify

Norden — Competitive Intelligence Brief

Norden (OCTOPAMINE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: octopamine. Area: Neuroscience.

marketed octopamine 5-hydroxytryptamine receptor 3A, Trace amine-associated receptor 1, Trace amine-associated receptor 1 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Norden (OCTOPAMINE). Norden works by binding to the 5-hydroxytryptamine receptor 3A, a subtype of serotonin receptor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Norden TARGET OCTOPAMINE marketed octopamine 5-hydroxytryptamine receptor 3A, Trace amine-associated receptor 1, Trace amine-associated receptor 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (octopamine class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Norden — Competitive Intelligence Brief. https://druglandscape.com/ci/octopamine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing